“OndekTM is harnessing the special properties of a common gut bacterium to re-balance the immune system and improve the management of allergy.”
Dr Barry Marshall
Nobel Laureate of Medicine and Physiology 2005 and Founder of OndekTM
ImmBALANCETM is being developed and patented by OndekTM as a natural ingredient for the development of a range of products for the management of allergic indications. This ingredient harnesses the immune regulatory properties of a common bacterium Helicobacter pylori, that naturally resides in the human gut. These products will be positioned as a family of premium immune-regulators that restore balance to the human immune system.
OndekTM featured on Catalyst, Australia’s primary science journalism TV series
2 October 2014
OndekTM Awarded $920,000 for Clinical Study of Allergy Product
24 February 2014
Australian biotechnology company Ondek Pty Ltd today announced it has been awarded an NH&MRC Development Grant of $919,596 to subsidise a clinical trial on its first allergy product. The trial will be conducted with its clinical partners, Professor Susan Prescott and Professor Peter Richmond, Princess Margaret Hospital for Children in Perth, and Professor Kate Allen, The Royal Children’s Hospital in Melbourne.
*World Allergy Organisation, White Book 2011